- Home
- HBNC vs GYRE Comparison
HBNC vs GYRE Comparison
Compare HBNC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBNC
- GYRE
- Stock Information
- Founded
- HBNC 1873
- GYRE 2002
- Country
- HBNC United States
- GYRE United States
- Employees
- HBNC N/A
- GYRE N/A
- Industry
- HBNC Major Banks
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- HBNC Finance
- GYRE Health Care
- Exchange
- HBNC Nasdaq
- GYRE Nasdaq
- Market Cap
- HBNC 826.6M
- GYRE 755.7M
- IPO Year
- HBNC N/A
- GYRE N/A
- Fundamental
- Price
- HBNC $16.12
- GYRE $8.19
- Analyst Decision
- HBNC Buy
- GYRE Strong Buy
- Analyst Count
- HBNC 3
- GYRE 2
- Target Price
- HBNC $19.67
- GYRE $17.00
- AVG Volume (30 Days)
- HBNC 357.8K
- GYRE 56.3K
- Earning Date
- HBNC 10-22-2025
- GYRE 11-07-2025
- Dividend Yield
- HBNC 4.00%
- GYRE N/A
- EPS Growth
- HBNC N/A
- GYRE N/A
- EPS
- HBNC N/A
- GYRE 0.04
- Revenue
- HBNC N/A
- GYRE $107,265,000.00
- Revenue This Year
- HBNC $51.78
- GYRE $15.25
- Revenue Next Year
- HBNC $7.40
- GYRE $33.14
- P/E Ratio
- HBNC N/A
- GYRE $209.75
- Revenue Growth
- HBNC 1.91
- GYRE 2.13
- 52 Week Low
- HBNC $12.70
- GYRE $6.11
- 52 Week High
- HBNC $19.18
- GYRE $14.88
- Technical
- Relative Strength Index (RSI)
- HBNC 53.29
- GYRE 54.94
- Support Level
- HBNC $15.95
- GYRE $7.12
- Resistance Level
- HBNC $16.44
- GYRE $8.38
- Average True Range (ATR)
- HBNC 0.34
- GYRE 0.35
- MACD
- HBNC 0.04
- GYRE 0.06
- Stochastic Oscillator
- HBNC 66.51
- GYRE 78.09
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.